Shopping Cart
- Remove All
Your shopping cart is currently empty
ICSN3250 HCl
🥰Excellent
Catalog No. T70442LCas No. 1561902-79-1
Alias ICSN3250 HCl（1561902-73-5 Free base), ICSN 3250 HCl
ICSN3250 HCl is the salt form of ICSN3250.ICSN3250 is an mTOR inhibitor that specifically targets cancer cells, competing with and displacing phosphatidic acid in the FRB structural domain of mTOR, thereby preventing mTOR activation and leading to cytotoxicity.
ICSN3250 HCl
🥰Excellent
Purity: 99.60%
Catalog No. T70442LAlias ICSN3250 HCl（1561902-73-5 Free base), ICSN 3250 HClCas No. 1561902-79-1
ICSN3250 HCl is the salt form of ICSN3250.ICSN3250 is an mTOR inhibitor that specifically targets cancer cells, competing with and displacing phosphatidic acid in the FRB structural domain of mTOR, thereby preventing mTOR activation and leading to cytotoxicity.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $195 | In Stock | |
| 5 mg | $483 | In Stock | |
| 10 mg | $692 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ICSN3250 HCl"
Bimiralisib
PQR309, PI3K-IN-2, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
T22651225037-39-7
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
- $30
Size
QTY
Everolimus
Cited
SDZ-RAD, RAD001
T1784159351-69-6
Everolimus (SDZ-RAD) is a potent mTOR inhibitor that binds to FKBP-12. It is used alone or in combination with calcineurin inhibitors.
- $37
Size
QTY
CitedPI3K/Akt/mTOR-IN-2
T605642757804-89-8In house
PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.
- $33
Size
QTY
Salidroside
Rhodioloside
T271710338-51-9
Salidroside is a bioactive phenolic glycoside compound isolated from Rhodiola rosea and is a prolyl endopeptidase inhibitor. Salidroside can alleviate cachexia symptoms in a tumor cachexia mouse model by activating mTOR signaling and protect dopaminergic neurons by enhancing PINK1/Parkin-mediated mitochondrial autophagy. Salidroside can also inhibit the growth of cancer cells by regulating the CDK4-cyclin D1 pathway to block the G1 phase and/or regulating the Cdc2-cyclin B1 pathway to block the G2 phase.
- $52
Size
QTY
GDC0084
RG7666, Paxalisib, GDC-0084, GDC 0084
T37051382979-44-3
GDC0084 (RG7666) is a PI3K inhibitor with potential antineoplastic activity. GDC0084 (RG7666) specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations.
- $36
Size
QTY
TMBIM6 antagonist-1
BIA, BAX-inhibitor-1
T8649123134-61-2
TMBIM6 antagonist-1 (BAX-inhibitor-1) is a bax inhibitor
- $85
Size
QTY
Sapanisertib
TAK-228, MLN0128, INK 128
T18381224844-38-5
Sapanisertib (INK 128) is an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
- $34
Size
QTY
P-2281
P2281, P 2281
T282851112994-35-0
P-2281 is an mTOR inhibitor with anticancer and anti-inflammatory properties.P-2281 inhibits dextran sulfate sodium (DSS)-induced colitis by suppressing T-cell function and is effective in a mouse model of human colitis.
- $158
Size
QTY
Capivasertib Cited
AZD5363
T19201143532-39-1
Capivasertib (AZD5363) is a broad-spectrum AKT inhibitor with inhibitory activity against Akt1, Akt2, and Akt3 (IC50=3/7/7 nM) with oral activity. Capivasertib has antitumor activity for the treatment of breast cancer.
- $34
Size
QTY
CitedL-Leucine
Leu, (S)-Leucine
T3O274961-90-5
L-Leucine ((S)-Leucine) is one of nine essential amino acids in humans (provided by food), L-Leucine is important for protein synthesis and many metabolic functions. L-Leucine contributes to regulation of blood-sugar levels; growth and repair of muscle and bone tissue; growth hormone production; and wound healing. L-Leucine also prevents breakdown of muscle proteins after trauma or severe stress and may be beneficial for individuals with phenylketonuria. L-Leucine is available in many foods and deficiency is rare.
- $42
Size
QTY
Rapamycin Cited
Sirolimus, NSC-2260804, AY 22989
T153753123-88-9
Rapamycin (AY 22989) is a natural product of macrolides, an mTOR inhibitor with specificity (HEK293 cells: IC50=0.1 nM). Rapamycin has immunosuppressive activity and induces autophagy.
- $30
Size
QTY
Citedα-Hydroxyglutaric Acid Lithium
α-Hydroxyglutaric Acid Lithium(2889-31-8 Free base)
T36624LIn house
α-Hydroxyglutaric Acid Lithium, converted from glutamate in microorganisms and animals, is an inhibitor of α-ketoglutarate-dependent dioxygenase and 5-methylcytosine hydroxylase, and has an inhibitory effect on ATP synthase and mTOR signaling.
- $34
Size
QTY
Select Batch
Purity:99.60%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | ICSN3250 HCl is the salt form of ICSN3250.ICSN3250 is an mTOR inhibitor that specifically targets cancer cells, competing with and displacing phosphatidic acid in the FRB structural domain of mTOR, thereby preventing mTOR activation and leading to cytotoxicity. |
| In vitro | ICSN3250 HCl was tested on multiple cancer cell lines (HCT116, U2OS, U87, K562) and normal cells (HUVEC, NHDF, HFDPC) under standard culture conditions (10–100 nmol/L, 24–72 h). Western blot, autophagy markers, and viability assays were used to assess activity. Results showed ICSN3250 HCl selective mTORC1 inhibition and cytotoxicity in cancer cells with minimal toxicity to normal cells[1]. |
| In vivo | Ex vivo: ICSN3250 HCl (100 nmol/L, 72 h) was applied to primary colorectal cancer cells and matched fibroblasts isolated from patient tumor tissue. Cell viability and morphology were assessed microscopically. ICSN3250 HCl selectively reduced cancer cell viability without affecting normal fibroblasts[1]. |
| Alias | ICSN3250 HCl（1561902-73-5 Free base), ICSN 3250 HCl |
| Molecular Weight | 633.13 |
| Formula | C31H41ClN4O8 |
| Cas No. | 1561902-79-1 |
| Smiles | Cl.O=N(=O)C=1C=C(C=C(O)C1O)C2=CN(C=C2C=3C=C(O)C(O)=C(C3)N(=O)=O)CCCN4CCCCCCCCCCCC4 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ICSN3250 HCl | purchase ICSN3250 HCl | ICSN3250 HCl cost | order ICSN3250 HCl | ICSN3250 HCl chemical structure | ICSN3250 HCl in vivo | ICSN3250 HCl in vitro | ICSN3250 HCl formula | ICSN3250 HCl molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.